

PD 123319

## Chemical Properties


CAS No. : 130663-39-7

Formula: C<sub>31</sub>H<sub>32</sub>N<sub>4</sub>O<sub>3</sub>

Molecular Weight: 508.61

Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



## Biological Description

Description	PD 123319 ((S)-(+)-PD 123319) is a potent, selective AT <sub>2</sub> angiotensin II receptor antagonist.
Targets(IC <sub>50</sub> )	RAAS
In vitro	Intravenous administration of PD 123319 to conscious hypertensive rats caused an immediate dose-dependent increase in MAP, and this effect was maintained for approximately 7.4 min with 3 mg/kg of PD 123319. PD 123319 had no effect on the self-regulation of cerebral blood flow.
In vivo	<sup>125</sup> I-AII specifically labeled two classes of AII binding sites in bovine adrenal glomerular cell membrane preparations. The first class (DuP-753-sensitive) accounted for approximately 85% of the total AII binding sites and had a high affinity for DuP-753 (IC <sub>50</sub> of 92.9 nM). PD-123319 had no effect on the binding of <sup>125</sup> I-AII to this site. The second type of binding site is more sensitive to PD-123319, with an IC <sub>50</sub> of 6.9 nM, and has a much lower affinity for DuP-753 (IC <sub>50</sub> of about 10 μM).

## Solubility Information

Solubility	DMSO: 55 mg/mL (108.14 mM), Sonication is recommended. H <sub>2</sub> O: 196.6 mM, Sonication is recommended. ( < 1 mg/ml refers to the product slightly soluble or insoluble)
------------	--

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.9661 mL	9.8307 mL	19.6614 mL
5 mM	0.3932 mL	1.9661 mL	3.9323 mL
10 mM	0.1966 mL	0.9831 mL	1.9661 mL
50 mM	0.0393 mL	0.1966 mL	0.3932 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Blankley CJ, et al. J Med Chem, 1991, 34(11), 3248-3260.

Zhang L, Zhang B, Yu Y, et al. Angiotensin II Increases HMGB1 Expression in the Myocardium Through AT1 and AT2 Receptors When Under Pressure Overload. International Heart Journal. 2021: 20-384

Qu L, Jiao M, Zhang Z, et al. A strategy for selective screening of dual-target bioactive compounds against hypertrophic scar through inhibiting angiotensin II type 1 receptor while stimulating type 2 receptor from Chinese herbs. Chinese Medicine. 2025, 20(1): 15.

Boulay G, et al. Mol Pharmacol, 1992, 41(4), 809-815.

Estrup TM, et al. J Renin Angiotensin Aldosterone Syst, 2001, 2(3), 188-192.

Tamura M, et al. J Hypertens, 2000, 18(9), 1239-1246.

Zhang L, Zhang B, Yu Y, et al. Angiotensin II Increases HMGB1 Expression in the Myocardium Through AT1 and AT2 Receptors When Under Pressure Overload[J]. International Heart Journal. 2021: 20-384

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481